Corbus Pharmaceuticals Holdings (STU:3371) FCF Margin %: 0.00% (As of Mar. 2026)


STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
31 GF Score
Price €7.57
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings FCF Margin %?

Corbus Pharmaceuticals Holdings STU:3371 +5.36% 31 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:3371 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Corbus Pharmaceuticals Holdings ranks worse than 104275.18% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Corbus Pharmaceuticals Holdings's Free Cash Flow for the three months ended in Mar. 2026 was €-22.12 Mil. Corbus Pharmaceuticals Holdings's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Corbus Pharmaceuticals Holdings's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Corbus Pharmaceuticals Holdings's current FCF Yield % is -45.74%.

The historical rank and industry rank for Corbus Pharmaceuticals Holdings's FCF Margin % or its related term are showing as below:


During the past 13 years, the highest FCF Margin % of Corbus Pharmaceuticals Holdings was -134.09%. The lowest was -5469.16%. And the median was -948.41%.

STU:3371's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Corbus Pharmaceuticals Holdings FCF Margin % Related Terms

Corbus Pharmaceuticals Holdings FCF Margin % Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings FCF Margin % Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,466.20 0.00 0.00 0.00 0.00

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:3371 vs AGEN, HURA, SLNCF: FCF Margin % Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's FCF Margin % falls into.


STU:3371
31GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Corbus Pharmaceuticals Holdings's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-55.081/0
= %

Corbus Pharmaceuticals Holdings's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-22.124/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Corbus Pharmaceuticals Holdings (STU:3371) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Corbus Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 959 companies in the Biotechnology industry.
Is Corbus Pharmaceuticals Holdings' FCF Margin % too high?
Corbus Pharmaceuticals Holdings' current FCF Margin % is 0.00%. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' FCF Margin % compare to AGEN and HURA?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 959 companies for FCF Margin %. This places Corbus Pharmaceuticals Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Corbus Pharmaceuticals Holdings (STU:3371) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score

Get the complete analysis for STU:3371

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.57
Price